Article
Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.
Human vaccines & immunotherapeutics - 1 Dec 2026
Luan Tao, Fu Suneng, Liu Weiting, Wang Shuaiying, Xie Xiaohong, Lin Xinqing, Chenli Zekun, Wang Liqiang, Ma Kangjing, Ma Hongbin, Mo Junyi, Yu Baodan, Yang Qingqing, Xu Yilin, Jin Hui, Chen Qishan, Yao Leyang, Luan Yang, Zhong Nanshan, Lv Qun, Zhang Yunhui, Zhou Chengzhi
Abstract excerpt
Human Epidermal Growth Factor Receptor 2 (HER2) mutations account for approximately 3% of non-small cell lung cancer (NSCLC) patients. Currently, targeted therapies for HER2-mutant NSCLC include HER2 tyrosine kinase inhibitors (TKIs) and HER2 Antibody-drug conjugates (ADC). However, resistance often develops, and effective treatments for HER2 mutations remain lacking. We report a case of HER2-mutant lung...
Topics
Join the communities discussing this publication.